Geode Capital Management
SBFM

Geode Capital Management’s Sunshine Biopharma SBFM Stock Holding History

Geode Capital Management’s Portfolio SBFM Stock Details SBFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1
Closed -$1.22K – 4616
2024
Q1 		$1.22K Hold
1
– – ﹤0.01% 4603
2023
Q4 		$5.48K Hold
1
– – ﹤0.01% 4634
2023
Q3 		$6.28K Hold
1
– – ﹤0.01% 4744
2023
Q2 		$9.98K Hold
1
– – ﹤0.01% 4716
2023
Q1 		$14.1K Hold
1
– – ﹤0.01% 4742
2022
Q4 		$12K Hold
1
– – ﹤0.01% 4830
2022
Q3 		$15K Hold
1
– – ﹤0.01% 4947
2022
Q2 		$21K Hold
1
– – ﹤0.01% 4915
2022
Q1 		$49K Buy
+1
New +$48.7K ﹤0.01% 4808

Other funds holding SBFM

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
MSG
Main Street Group Glen Allen, Virginia $429M AUM 34.03% 1-Year Est. Return

Geode Capital Management's SBFM Position: Q2 2024 in Review

Geode Capital Management sold out of Sunshine Biopharma (SBFM) in Q2 2024, closing a stake of 1 share — an estimated $1.22K sold.

Geode Capital Management first reported a position in SBFM in Q1 2022 and held it in 9 quarters. The position peaked at $49K in Q1 2022. 8 funds tracked by Wall St. Rank hold SBFM as of Q2 2024.

  • Geode Capital Management reported no remaining Sunshine Biopharma position as of Q2 2024 after selling out during the quarter.
  • Geode Capital Management sold 1 Sunshine Biopharma share in Q2 2024, an estimated $1.22K.
  • Geode Capital Management first reported a position in Sunshine Biopharma in Q1 2022 and held it in 9 quarters.
  • Geode Capital Management's Sunshine Biopharma position peaked at $49K in Q1 2022.
  • 8 funds tracked by Wall St. Rank held Sunshine Biopharma as of Q2 2024.

Based on Geode Capital Management's 13F filing for Q2 2024, filed 9 Aug 2024.